NeoGenomics has agreed to buy portfolio company Inivata, a liquid biopsy platform developer, a year after it invested $25m.

Inivata, a UK-based developer of precision cancer diagnostics technology, agreed today to a $390m acquisition by one of its investors, cancer diagnostics service provider NeoGenomics.

Founded in 2014, Inivata has created a liquid biopsy platform that can extract genomic information from a simple blood draw. The technology facilitates personalised cancer treatment by monitoring response to therapy and detecting relapse.

The company’s lead product, InVisionFirst-Lung, is aimed at patients suffering from advanced non-small-cell lung carcinoma. It is commercially available internationally, including…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn